Patents by Inventor Steven Almo

Steven Almo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Engineered PD-1 variants
    Patent number: 11905322
    Abstract: Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD- L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: February 20, 2024
    Assignee: Albert Einstein College of Medicine
    Inventors: Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei
  • Engineered PD-1 variants
    Patent number: 11352413
    Abstract: Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD-L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: June 7, 2022
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventors: Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei
  • ENGINEERED PD-1 VARIANTS
    Publication number: 20220098274
    Abstract: Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD-L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.
    Type: Application
    Filed: May 3, 2021
    Publication date: March 31, 2022
    Inventors: Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei
  • ENGINEERED PD-1 VARIANTS
    Publication number: 20190127439
    Abstract: Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD-L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.
    Type: Application
    Filed: May 9, 2017
    Publication date: May 2, 2019
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei